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Abstract
Objective:Childrenwith congenital diaphragmatic hernia (CDH) suffer from long-term
pulmonary morbidity. Longitudinal data of exercise capacity in these children are
lacking. We hypothesized that exercise capacity would be impaired in children with
CDH and deteriorates over time.We evaluated exercise capacity and its determinants
in CDH patients longitudinally until 12 years of age.
Design: Prospective longitudinal follow-up study in tertiary university hospital.
Patients:Onehundred and fourteen childrenwith CDHborn between 1999 and 2012.
Methods: Exercise capacity was evaluated using the Bruce treadmill-protocol at the
ages of 5, 8, and 12 years. Primary outcome parameter was standard deviation score
(SDS) of maximal endurance time. Data were analyzed by using linear mixed models.
Results:Atotal of 107children (30 treatedwithextracorporealmembraneoxygenation
[ECMO]) performed 191 reliable exercise tests. At ages 5, 8, and 12 years, the mean
(95%CI) SDSendurance timewas−0.44 (−0.65 to−0.24);−1.01 (−1.23 to−0.78);−1.10
(−1.40 to −0.80), respectively, all less than zero (P < 0.001). Exercise capacity declined
significantly over time irrespective of ECMO-treatment (5-12 years: non-ECMO
P = 0.015; ECMO P = 0.006). Duration of initial hospital stay and diffusion capacity
corrected for alveolar volumewere associatedwith SDSendurance time (P < 0.001 and
P = 0.039).
Conclusions: InCDHpatients exercise capacity deteriorates between5and12years of
age, irrespective of ECMO-treatment. CDH patients may benefit from long-term
assessments of exercise capacity with timely intervention.
K E YWORD S
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1 | INTRODUCTION
Congenital diaphragmatic hernia (CDH) occurs in 1 in 3000-4000
births.1 Although CDH is still a life-threatening anomaly, survival rates
have increased over the past decades.2 Advances in surgical and
neonatal management, as well as the implementation of a standardized
European neonatal treatment protocol in November 20073 (Table 1 of
the online supplement), have significantly contributed to higher survival
rates2 which turned out to be sustainable over time and inmany centers
around theworld.With the increased survival, more childrenmay suffer
from long-term morbidities, including pulmonary symptoms. Factors
that may contribute to long-term pulmonary morbidity are lung
hypoplasia with persistent airflow obstruction,4,5 iatrogenic lung
damage due to mechanical ventilation,4 and microstructural changes
in the lung.6 These pulmonary abnormalities may lead to decreased
exercise capacity on the long-term and affect development in later life.
While several studies found decreased exercise capacity in CDH
patients at school-age,7–11 a few other studies showed normal exercise
capacity in school-aged5,12 and inadultCDHpatients.13,14These studies
had mostly a cross-sectional study design, small sample sizes, and
included patients born before a standardized postnatal treatment
protocolbecameavailable.A longitudinalevaluationofexercisecapacity
in CDH patients has not been performed to date.
Therefore, the aim of the present study was to evaluate
longitudinally exercise capacity at the ages of 5, 8, and 12 years in a
large cohort of CDH patients treated with or without neonatal
extracorporeal membrane oxygenation (ECMO). Secondarily, we
aimed to find clinical determinants of exercise capacity. Furthermore,
we evaluated whether the implementation of a standardized postnatal
treatment protocol influenced exercise capacity.
TABLE 1 Patient characteristics
Background Total n = 107 ECMO n = 30 non-ECMO n = 77 P
Gestational age (weeks) 38.6 ± 1.9 39.0 ± 1.6 38.4 ± 2.1 0.105
Birth weight (kilograms) 3.0 ± 0.6 3.2 ± 0.4 3.0 ± 0.6 0.154
Male (%) 62 (57.9) 20 (66.7) 42 (54.5) 0.254
Ethnicity 0.331
Dutch (%) 88 (82.2) 23 (76.7) 65 (84.4)
Other (%) 19 (17.8) 7 (23.3) 12 (15.6)
Left-sided hernia (%) 93 (86.9) 27 (90.0) 66 (85.7) 0.555
Patch repair (%) 75 (70.1) 26 (86.7) 49 (63.6) 0.019
Days of mechanical ventilation 11 (6-22) 29 (16-48) 8 (5-16) <0.001
Ventilator-free daysa 17 (6-22) 0 (0-12) 20 (12-23) <0.001
Type of initial mechanical ventilation 0.811
CMV 45 (42.1) 12 (40.0) 33 (42.9)
HFO 59 (55.1) 17 (56.7) 42 (54.5)
No ventilation 1 (0.9) – 1 (1.3)
Missing 2 (1.9) 1 (3.3) 1 (1.3)
Days of ICU stay 20 (13-42) 52 (29-80) 16 (10-27) <0.001
Days of initial hospital stay 36 (20-61) 80 (36-102) 27 (27-50) <0.001
Bronchopulmonary dysplasia (%) <0.001
No 68 (63.6) 11 (36.7) 57 (74.0)
Mild 16 (15.0) 3 (10.0) 13 (16.9)
Moderate 4 (3.7) 3 (10.0) 1 (1.3)
Severe 17 (15.9) 13 (43.3) 4 (5.2)
Missing 2 (1.8) – 2 (2.6)
Congenital heart diseaseb 9 (8.8) 5 (16.7) 4 (5.2) 0.055
PDE5 treatment 13 (12.1) 9 (30.0) 3 (3.8) <0.001
aVentilator-free days in the first 28 days of life.
bCongenital heart disease: Ventricle SeptumDefect (n = 1), Atrium SeptumDefect (n = 2), Ventricle SeptumDefect and Atrium SeptumDefect (n = 1), Double
Outlet Right Ventricle + transposition blood vessel + Open Foramen Ovale + Open Ductus Botalli (n = 1), Open Ductus Botalli + Open Foramen
Ovale + tricuspidalis and mitral insufficiency (n = 1), Open Ductus Botalli + Atrium Septum Defect with surgery (n = 2), dysplastic pulmonic valve and
tricuspidalis insufficiency (n = 1).
Data are presented as mean ± standard deviation, median (interquartile range) or number (percentage), as appropriate. ECMO= extracorporeal membrane
oxygenation, PDE5 treatment = treatment with phosphodiesterase type 5 inhibitor.
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2 | MATERIALS AND METHODS
2.1 | Patients, procedures, and study design
We included all CDH patients born between January 1999 and
May 2012 who joined our prospective, multidisciplinary follow-up
program at the Erasmus MC-Sophia Children's Hospital. This program
conforms to the present standard of care for children born with major
anatomical congenital anomalies, including ECMO treatment if
needed. In this program, the children and their parents are followed
by a multidisciplinary team, and eight standardized assessments are
performed between 0.5 and 17 years of age.10,15
We excluded data from patients diagnosed with CDH after seven
days of age, those with paraesophageal diaphragmatic defects, those
with a diaphragmatic eventration, and those with psychomotor
disabilitieswho could not perform amaximal cardiopulmonary exercise
test. Until November 2007, ECMO treatment was applied in cases of
reversible severe respiratory failure by using the entry criteria reported
by Stolar et al.16 After November 2007, children were treated
according to the standardized CDH EURO Consortium consensus
treatment protocol3 which included similar ECMO criteria (Table 1 of
the online supplement).
A pediatrician and a pediatric surgeon performed standardized
physical examination. Exercise capacity was evaluated by an experi-
enced pediatric physical therapist. Standardized information (type and
frequency of sports participation other than gymnastics) was recorded
about sports participation. Prior to the exercise test, parents estimated
their child's fitness level as higher, equal to or less than that of children
with the same age. Perinatal and demographic characteristics were
retrieved frommedical records. The last included patient was tested in
July 2017.
The Medical Ethics Committee of the Erasmus MC stated that the
rules laid down in theMedical Research Involving Human Subjects Act
and did not apply to this research proposal (MEC-2016-111). Parents
of all children were routinely informed about the study and provided
permission to use the data for research purposes.
2.2 | Measurements
2.2.1 | Baseline data
The following baseline data were recorded: gender, age, gestational
age, birth weight, ethnicity, side hernia, type of repair, duration of
mechanical ventilation, ventilation-free days in the first 28 days of life,
type of initial mechanical ventilation, duration of intensive care unit
(ICU) stay, duration of initial hospital stay, presence of chronic lung
disease (CLD),17 congenital cardiac anomalies, treatment with
phosphodiesterase type 5 inhibitor, and sports participation. More-
over, we assessed lung function. Forced expiratory volume in 1 s
(FEV1) was assessed with an electronic spirometer (Masterscreen PFT,
Carefusion, SanDiego, CA) after inhalation of 400 μg salbutamol18 and
expressed as absolute value and as SDS.19 Total lung capacity (TLC)
was determined by whole body plethysmography (Masterscreen Body
Plethysmography, Carefusion, San Diego, CA) and expressed as
absolute value and percentile score. Diffusion capacity corrected for
alveolar volume (KCO) was measured using a multigas analyzer
(Masterscreen PFT, Carefusion, San Diego, CA) by the single-breath
method. Percentile scores for static lung volumes and diffusion
capacity obtained by the reference equations of Koopman et al20 were
transformed into SDS using an inverse normal transformation.
2.2.2 | Exercise capacity
All children performed a maximal cardiopulmonary exercise test after
the lung function assessment, that is, 1-2 h after inhalation of
salbutamol if applicable. Therefore, we evaluated only lung function
after bronchodilation (BD). Themaximal cardiopulmonary exercise test
was performed on a motordriven treadmill (En Mill; Enraf Nonius,
Rotterdam, the Netherlands), programmed for increases in angle of
inclination and speed according to the Bruce protocol.21,22 The
children were encouraged to perform to exhaustion. The maximal
endurance time (in minutes, one decimal) served as criterion of
exercise capacity, with SDS based on reference values for healthy
Dutch children.21,22 Heart rate and transcutaneous oxygen saturation
were monitored before and during the test with a pulse oximeter
(MARS (Motion Artifact Reduction System), type 2001; Respironics
Novametrix, Murrysville, PA). Heart rate of ≥185 beats per min23 or
loss of coordination because of excessive fatiguewas taken asmaximal
performance.
2.3 | Statistical analysis
Differences in baseline data between “participants in the follow-up
program” and “non-participants in the follow-up program” and the
children “treated with neonatal ECMO” and “not treated with
neonatal ECMO” were evaluated using Mann-Whitney U tests for
continuous variables and chi-square tests for categorical variables.
One-sample t-tests were used to test whether the normally
distributed data of exercise capacity differed from population norms
(SDS = 0). To test whether exercise capacity differed between ECMO
treated CDH patients and non-ECMO treated CDH patients,
independent samples t-tests were used. Longitudinal evaluation of
the endurance times at 5, 8, and 12 years of age was performed
using linear mixed-models, which can account for within-subject
correlations and allows for missing values in the dependent
variable.24 To investigate whether perinatal and demographic
characteristics had a significant influence on SDS endurance time,
we considered the following list of baseline data in the linear mixed-
model as covariates: gestational age, ECMO treatment, use of a
standardized treatment protocol (after November 2007), patch
repair, duration of initial hospital stay, ventilator-free days in the first
28 days of life, type of initial mechanical ventilation, congenital
cardiac malformation, and sports participation. We used a stepwise
backward approach to select covariates from this list of baseline
data. Two-way interaction effects were then added to the resulting
model if the interaction effect was statistically significant. The
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results of the linear mixed-models are reported using estimated
marginal means, which are the predicted values of the dependent
variable adjusted for the effect of covariates. To investigate whether
lung function parameters (FEV1, TLC, KCO) had a significant influence
on SDS endurance time, only data of exercise capacity at the ages of
8 and 12 years was used, as lung function was not measured at the
age of 5. Therefore, separate linear mixed-models were performed
with the above-mentioned list of baseline data and FEV1, TLC and
KCO as covariates at 8 and 12 years of age. Multicollinearity was
assessed using variance inflation factors (VIFs). VIFs ≤5.0 were
considered acceptable, whereas higher values were taken as a sign of
multicollinearity. Spearman's rank correlation was used to test
whether the levels of exercise capacity as estimated by the parents
was associated with the measured SDS endurance time.
Analyses were performed using SPSS 21.0 (IBM, Chicago, IL), and
all statistical tests used a two-sided significance level of 0.05.
3 | RESULTS
3.1 | Patients
Between January 1999 and July 2012, 234 children were born with
CDH in the Erasmus MC—Sophia Children's Hospital. Sixty-five
(27.7%) died before hospital discharge (Figure 1). Fifty-five (32.4%)
of the 169 survivors were excluded for various reasons (Figure 1).
Thus, 114 (67.1%) performed the Bruce-protocol (220measurements).
We excluded the results of 29 measurements (13.8%) because
maximal performance was not achieved (Figure 1). The analysis for
this study concerned 191 reliable tests performed by 107 children
(62.9 % of all survivors), of whom 30 (28.0%) had received ECMO
treatment.
Patient characteristics are presented in Table 1. Duration of
mechanical ventilation, ventilator- free days within the first 28 days of
life, PICU stay and duration of initial hospital stay differed significantly
between children treated with and without ECMO. Also the presence
of CLD, treatment with phosphodiesterase type 5 inhibitor, and FEV1
after BD (at 8 years of age) were significantly different between these
groups (Table 1). No differences in background characteristics, except
for ethnicity (P = 0.001) and birthweight (P = 0.030), were found
between the participants and non-participants of our follow-up
program (data not shown).
3.2 | Exercise capacity
The estimated marginal mean (95% confidence interval (CI)) SDS
endurance time was significantly below the norm at all ages: 5 years:
−0.44 (−0.65 to −0.24); 8 years: −1.01 (−1.23 to−0.78); 12 years: −1.10
(−1.40 to −0.80) (all P < 0.001) (Table 3). The mean (SD) heart rate at
maximal exercise was 191 (9.0) beats per minute and the median (IQR)
transcutaneous oxygen saturation at maximal exercise was 98% (96-
99). Exercise capacity decreased significantly from the ages of 5 to 8
years (P < 0.001) and from 5 to 12 years (P < 0.001) (Table 2 of the
online supplement).
3.3 | ECMO treated CDH patients versus non-ECMO
treated CDH patients
Exercise capacity differed significantly between ECMO treated and
non-ECMO treated patients (mean difference (95%CI) 0.421 (0.117 to
0.724, P = 0.007), particularly at the age of 8 (P = 0.036). Exercise
capacity declined significantly in ECMO treated patients from 5 to
8 years (P = 0.001) and from 5 to 12 years (P = 0.006). This decline was
also seen in non-ECMO treated patients; from 5 to 8 years (P = 0.008)
and 5 to 12 years (P = 0.015) (Table 3, Figure 2, Table 2 of the online
supplement).
3.4 | Associations between exercise capacity and
baseline data
Exercise capacity was significantly negatively associated with the
duration of initial hospital stay (estimated coefficient (95%CI) −0.006
(−0.009 to 0.003), P < 0.001) and positively with KCO (estimated
coefficient (95%CI) 0.27 (0.01 to 0.53), P = 0.039). No other significant
associations were found between exercise capacity and timepoint of
assessment, gestational age, use of a new treatment protocol, patch
repair, ventilator free days in the first 28 days of life, type of initial
mechanical ventilation, congenital cardiac malformation, FEV1, TLC,
and sports participation (Table 3 of the online supplement). Although
exercise capacity differed significantly between ECMO treated and
non-ECMO treated patients—with lower exercise capacity in ECMO
treated patients—ECMO had no significant effect on the deterioration
of exercise capacity: no significant interaction-effect was found
between ECMO and time point of assessment for exercise capacity
(P = 0.363). For both groups the same trend in deterioration was
observed (Figure 2).
All VIFs were ≤3.1.
3.5 | Exercise capacity estimated by the parents
The levels of exercise capacity as estimated by the parents correlated
positively with the measured SDS endurance time (r = 0.420,
P < 0.001).
4 | DISCUSSION
Weevaluated longitudinally maximal exercise capacity in children with
CDH aged 5 to 12 years. Exercise capacity was significantly below the
norm at all ages, and declined significantly over time—not only in
children treated with ECMO but also in those who did not need ECMO
treatment. The duration of initial hospital stay and the diffusion
capacity of the lungs were associated with exercise capacity.
Treatment of neonates with CDH is challenging and therapeutic
strategies have changed over the decades. This has resulted in
decreasing mortality rates,2,25 and development of lung protecting
strategies, for example, gentle ventilation with permissive hypercap-
nia.26 Therefore, it is hard to compare the data of our population with
those who survived over 20 years ago.8,12–14,27,28 We previously
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found decreased exercise capacity in 5-year-old CDH patients,
irrespective of whether they had been treated with ECMO.10 In
another study, in children with different underlying diagnoses, who
had all been treated with neonatal ECMO, we showed that maximal
exercise capacity was below the norm at 5, 8, and 12 years and
deteriorated over time.11Many children in that study cohortwere born
in the early 1990s.11 Despite the differences in study population, a
similar course in deteriorating of exercise capacity was observed in the
current study. These findings suggest that exercise capacity should be
assessed in childhood and adolescence, and even into adulthood. The
FIGURE 1 Flowchart of the study population selection. aChromosome aberration (n = 2), Cohen syndrome (n = 1), Loeys-Dietz syndrome
(n = 1), Simpson-Golabi-Behmel syndrome (n = 3), Wolf-Hirschhorn syndrome (n = 1), autism (n = 3). bHemiplegia (n = 3), aortastenosis (n = 1),
tracheacanule (n = 1), severe chronic lung disease (n = 1), organizational reasons (n = 2), anxiety (n = 1). cLoss of coordination (n = 7), anxiety
(n = 7), refused (n = 2), no maximal performance (n = 10), loose shoelaces (n = 1), insufficient Dutch language (n = 1), calf muscle pain (n = 1).
CDH = congenital diaphragmatic hernia; ECMO= extracorporeal membrane oxygenation
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question remains, however, whether timely intervention indicated by
the assessment outcome may improve or at least prevent deteriora-
tion. Encouraging the children to engage in physical activity could help
prevent secondary morbidities. Pro-active counselling by physicians
and early referral to physical therapists may be useful.
The introduction of the postnatal treatment protocol of the CDH
EURO Consortium led to an increased survival of children born with
CDH.3 This protocol was implemented in our department in
November 2007. Standardization of postnatal management has
resulted in lower mortality but not a lower prevalence of CLD.2 This
suggests that more patients with CDH who develop CLD survive,
which may affect maximal exercise capacity. However, we could not
demonstrate a significant effect of the introduction of the protocol on
maximal endurance time (Tables 3 and 4 of the online supplement). The
effect of improved intensive caremight have been be counterbalanced
by a higher prevalence of survivors with CLD. Larger numbers of
children should be studied at 8 and 12 years to demonstrate a possible
effect of the implementation of the treatment protocol on exercise
capacity.
We assumed that children with more severe lung hypoplasia,
might be at the highest risk for impaired exercise capacity. Indeed,
children who had been treated with ECMO had significantly more
airflow obstruction and lower SDS endurance time. Interestingly, KCO
was significantly below the norm both in ECMO treated and non-
ECMO treated children and was positively associated with exercise
capacity, whereas ECMO treatment was not associated with exercise
capacity. We speculate that microstructural changes of the lungs,
which have been described in young adults with CDH,6 may already
occur at younger age. Future studies focusing on lung structure
imaging may be useful to identify patients at risk for clinical
deterioration and impaired exercise tolerance. The association
between initial hospital stay duration and exercise capacity that we
TABLE 2 Characteristics at follow-up assessments
At follow-up Total n = 107 ECMO n = 30 non-ECMO n = 77 P
At 5 years of age n = 87 n = 23 n = 64
Sports participation (%) 46 (52.9) 14 (60.9) 32 (50.0) 0.373
Referral to PPTa (%) 13 (14.9) 4 (17.4) 9 (14.1) 0.703
PPT continuationb (%) 8 (9.2) 4 (17.4) 4 (6.3) 0.115
At 8 years of age n = 69 n = 26 n = 43
SDS FEV1 −0.28 (−1.25 to 0.62) −1.02 (−1.82 to 0.56) −0.10 (−0.73 to 0.67) 0.024
SDS TLC −0.05 (−0.90 to 0.58) −0.07 (−1.04 to 0.39) −0.05 (−0.80 to 0.71) 0.576
SDS KCO −1.48 (−2.05 to −0.51) −1.64 (−2.33 to −0.99) −1.18 (−1.97 to −0.44) 0.172
Sports participation (%) 54 (78.3) 18 (69.2) 36 (83.7) 0.160
Referral to PPTa (%) 20 (28.9) 10 (38.4) 10 (23.7) 0.180
PPT continuationb (%) 2 (2.9) 1 (3.8) 2 (4.7) 0.717
At 12 years of age n = 35 n = 18 n = 17
SDS FEV1 −0.54 (−1.55 to 0.25) −1.10 (−2.52 to 0.24) −0.35 (−0.88 to 0.25) 0.136
SDS TLC 0.28 (−0.81 to 1.08) −0.15 (−1.07 to 0.66) 0.39 (−0.67 to 1.49) 0.159
SDS KCO −1.28 (−1.88 to −0.88) −1.48 (−2.33 to −0.20) −1.20 (−1.62 to −0.90) 0.446
Sports participation (%) 24 (68.6) 11 (61.1) 13 (76.5) 0.335
Referral to PPTa (%) 10 (28.6) 6 (33.3) 4 (23.5) 0.527
PPT continuationb (%) – – – –
aAfter follow-up assessment the patient was referred to a local community based pediatric physical therapist to start intervention.
bAfter follow-up assessment the patient was recommended to continue intervention by a local community based pediatric physical therapist.
Data are presented as median (interquartile range) or number (percentage), as appropriate. ECMO, extracorporeal membrane oxygenation.
TABLE 3 Endurance time of CDH patients treated with and without ECMO
5 years 8 years 12 years
All CDH patients, n = 107 −0.44 (−0.65 to −0.24)a −1.01 (−1.23 to −0.78)a −1.10 (−1.40 to −0.80)a
ECMO, n = 31 −0.63 (−1.04 to −0.21)b −1.34 (−1.74 to −0.94)a −1.32 (−1.77 to −0.86)a
non-ECMO, n = 71 −0.38 (−0.61 to −0.15)a −0.82 (−1.10 to −0.55)a −0.96 (−1.38 to −0.53)a
Data are presented as estimated marginal means (95% confidence intervals) SDS endurance time. Significantly below the population norm (SDS = 0):
aP ≤ 0.001; bP = 0.004.
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found suggests that the most critically ill neonates with the most
severe pulmonary problems are most likely to suffer from persistent
pulmonary morbidity later in life.
Besides, we speculate that parents of children who had been
critically ill as neonates may consider their child more vulnerable than
the parents of the child's healthy peers. For this reason, and also
because pulmonary morbidity persist for years,4,5 parents may not
encourage physical activities. This may, in turn, puts them at risk of
gross motor function problems29,30 and consequently reduced
participation in physical activities. Smith et al found similar problems
in children born very preterm. Reduced exercise capacity could not be
explained by airflow obstruction. Therefore, these authors also
hypothesized that children born very preterm are deconditioned and
that a lack of physical activitymight play a role.31 Although in our study
ECMO treatment had no significant influence on decreased exercise
capacity and its deterioration, we assume that the lower exercise
capacity in ECMO treated CDHpatients might be explained by the fact
that ECMO treated patients are the most critically ill children at
neonatal age with more severe lung hypoplasia, more airflow
obstruction, and less participation in physical activities.
Following this reasoning, the deterioration in exercise capacity
between the ages 5 and 8, and its stabilization from the ages of 8,
could perhaps partly be explained by sports participation. At the age
of 8 and 12 about two thirds of the children participated in sports
versus only half of them at the age of 5. Assumable, parents consider
their child in the first years of life more vulnerable and are reluctant
to encourage their children in daily physical activities and sports
participation.
The main strengths of this study are the longitudinal design
within the infrastructure of a standardized follow-up program, the
small proportion of children lost to follow-up and the relatively large
sample size for this rare congenital anomaly. Some limitations need
to be addressed. Not all children participating in the follow-up
program had reached the age of 12 years yet. The resulting small
number of children assessed at 12 years of age increases the
probability of a type II error, although mixed models account for data
missing at random. Secondly, postnatal management of CDH
changed during the study period, which could have influenced our
results as more children with severe lung hypoplasia survived after
introduction of the standardized postnatal treatment protocol. We
did not find a significant effect of the introduction of the postnatal
treatment protocol on exercise capacity (Tables 3 and 4 of the online
supplement), but larger sample sizes of 8-year-old and 12-year-old
children may be needed to detect a significant difference. Thirdly, we
used the maximal endurance time rather than the peak oxygen
consumption as measure of exercise capacity, mainly for reasons of
feasibility. Wearing a mask may lead to loss of cooperation and to
submaximal results, especially in the younger children. A strong
correlation between maximal endurance time and maximal oxygen
uptake has been reported by Cumming and coworkers.32 Besides,
since our setting is an outpatient clinic and not a primary research
setting, we feel that cardiopulmonary exercise testing (CPX), which
includes breath gas analysis, is too intensive to perform in every
CDH patient during routine follow-up. In future research projects in
our department, CPX in children will be evaluated, and conclusions
on exercise capacity in CDH patients might be extended. Fourthly,
we did not include a group of healthy controls. However, we used
recently established reference data collected in our own center.21,22
Fifthly, we had no data on physical activity. Reduced physical activity
might be one of the explanations for decreased exercise capacity in
children with CDH and is subject of an ongoing research project in
our center. Finally, considering the large amount of possible
determinants of exercise capacity, as well as the possibility of
multicollinearity we had to be critical which lung function
parameters to include as possible determinants in the mixed model
analysis. In a cross-sectional study of Peetsold et al,5 exercise
capacity and lung function was measured in school-aged children
born with CDH and having been referred either to the Paediatric
Surgical Centre of Amsterdam (the Netherlands) between 1987 and
1999, and to our center between 1988 and 1994. They showed no
associations between VO2max and lung function parameters, except
for FEV1 (R
2 = 0.27; P = 0.001). In another study of our research
group none of the lung function parameters, but DLCO was related to
VO2peak % pred. in young adult CDH patients.
14 Therefore, as
multicollinearity arose between lung function parameters in this
study, we critically chose to include only FEV1, TLC and KCO in the
mixed model analysis.
The significant differences in ethnicity and birthweight between
the participants and non-participants in this study was in line with
expectations. We found a higher percentage of other ethnicities than
Dutch and lower birthweight in the non-participant group. Native
Dutch parents and children showed higher follow-up and treatment
adherence than parents of other ethnicities.33 Differences in birth-
weight between ethnicities are common.34 Nevertheless, we will
pursue our strategies to enhance adherence in non-native Dutch
parents and children in our follow-up program. Background character-
istics that reflect severity of illness did not differ between the
FIGURE 2 Change in maximal exercise capacity over time in
children with CDH. Data shown are estimated marginal means from
the linear mixed-model analysis with 95% confidence intervals.
CDH = congenital diaphragmatic hernia; ECMO= extracorporeal
membrane oxygenation; SDS = standard deviation score
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participants and non-participants (data not shown). Selection bias is
likely not present.
5 | CONCLUSION
CDH patients were at risk for decreased exercise capacity at school-
age. Decreased exercise capacity deteriorated over time, not only in
children who had needed neonatal ECMO treatment but also in
children who had not needed ECMO. Exercise capacity was
significantly negatively associated with the duration of initial hospital
stay and positively with KCO. Early risk stratification for decreased
exercise capacity may be important to offer timely intervention.
Further studies are needed to unravel the causes of decreased exercise
capacity. We recommend prolonged follow-up, pro-active advice on
physical activities and sports participation or referral to a physical
therapist.
ACKNOWLEDGMENTS
We thank the staff of our long-term follow-up team, the technicians of
the lung function department of our hospital for their help in data
collection. Ko Hagoort provided editorial advice. No funding was
secured for this study.
ORCID
Hanneke IJsselstijn http://orcid.org/0000-0001-5824-3492
REFERENCES
1. Ackerman KG, Pober BR. Congenital diaphragmatic hernia and
pulmonary hypoplasia: new insights from developmental biology
and genetics. Am J Med Genet C Semin Med Genet.
2007;145C:105–108.
2. Van Den Hout L, Schaible T, Cohen-Overbeek TE, et al. Actual
outcome in infants with congenital diaphragmatic hernia: the role of a
standardized postnatal treatment protocol. Fetal Diagn Ther.
2011;29:55–63.
3. Reiss I, Schaible T, van den Hout L, et al. Standardized postnatal
management of infants with congenital diaphragmatic hernia in
Europe: the CDH EURO Consortium consensus. Neonatology.
2010;98:354–364.
4. Spoel M, Laas R, Gischler SJ, et al. Diagnosis-related deterioration of
lung function after extracorporeal membrane oxygenation. Eur Respir
J. 2012;40:1531–1537.
5. Peetsold MG, Heij HA, Nagelkerke AF, et al. Pulmonary function and
exercise capacity in survivors of congenital diaphragmatic hernia. Eur
Respir J. 2009;34:1140–1147.
6. Spoel M, Marshall H, IJsselstijn H, et al. Pulmonary ventilation and
micro-structural findings in congenital diaphragmatic hernia. Pediatr
Pulmonol. 2016;51:517–524.
7. Trachsel D, Selvadurai H, Adatia I, et al. Resting and exercise
cardiorespiratory function in survivors of congenital diaphragmatic
hernia. Pediatr Pulmonol. 2006;41:522–529.
8. Zaccara A, Turchetta A, Calzolari A, et al. Maximal oxygen consump-
tion and stress performance in children operated on for congenital
diaphragmatic hernia. J Pediatr Surg. 1996;31:1092-1094; discussion
1095.
9. Turchetta A, Fintini D, Cafiero G, et al. Physical activity, fitness, and
dyspnea perception in children with congenital diaphragmatic hernia.
Pediatr Pulmonol. 2011;46:1000–1006.
10. Gischler SJ, van der Cammen-van Zijp MHM, Mazer P, et al.
A prospective comparative evaluation of persistent respiratory
morbidity in esophageal atresia and congenital diaphragmatic hernia
survivors. J Pediatr Surg. 2009;44:1683–1690.
11. van der Cammen-van Zijp MH, Gischler SJ, Hop WC, de Jongste JC,
Tibboel D, IJsselstijn H. Deterioration of exercise capacity after
neonatal extracorporeal membrane oxygenation. Eur Respir J.
2011;38:1098–1104.
12. Marven SS, Smith CM, Claxton D, et al. Pulmonary function, exercise
performance, and growth in survivors of congenital diaphragmatic
hernia. Arch Dis Child. 1998;78:137–142.
13. PeetsoldMG, Vonk-Noordegraaf A, Heij HH, Gemke RJBJ. Pulmonary
function and exercise testing in adult survivors of congenital
diaphragmatic hernia. Pediatr Pulmonol. 2007;42:325–331.
14. van der Cammen-van ZijpMH, SpoelM, Laas R, et al. Exercise capacity,
daily activity, and severity of fatigue in term born young adults after
neonatal respiratory failure. Scand JMed Sci Sports. 2014;24:144–151.
15. Mazer P, Gischler SJ, Cammen-VAN Zijp VANDERMH, et al. Early
developmental assessment of children with major non-cardiac
congenital anomalies predicts development at the age of 5 years.
Dev Med Child Neurol. 2010;52:1154–1159.
16. Stolar CJ, Snedecor SM, Bartlett RH. Extracorporeal membrane oxygen-
ation andneonatal respiratory failure: experience from theextracorporeal
life support organization. J Pediatr Surg. 1991;26:563–571.
17. Jobe AH, Bancalari EH. Controversies about the definition of broncho-
pulmonary dysplasia at 50 years. Acta Paediatr. 2017;106:692–693.
18. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of
spirometry. Eur Respir J. 2005;26:319–338.
19. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values
for spirometry for the 3-95-yr age range: the global lung function 2012
equations. Eur Respir J. 2012;40:1324–1343.
20. Koopman M, Zanen P, Kruitwagen CL, van der Ent CK, Arets HG.
Reference values for paediatric pulmonary function testing: the
Utrecht dataset. Respir Med. 2011;105:15–23.
21. van der Cammen-van ZijpMH, van den Berg-Emons RJ,Willemsen SP,
Stam HJ, Tibboel D, IJsselstijn H. Exercise capacity in Dutch children:
new reference values for the Bruce treadmill protocol. Scand J Med Sci
Sports. 2010;20:e130–e136.
22. van der Cammen-van ZijpMHM, IJsselstijn H, Takken T, et al. Exercise
testing of pre-school children using the Bruce treadmill protocol: new
reference values. Eur J Appl Physiol. 2010;108:393–399.
23. Karila C, de Blic J, Waernessyckle S, Benoist MR, Scheinmann P.
Cardiopulmonary exercise testing in children − An individualized
protocol for workload increase. Chest. 2001;120:81–87.
24. Fitzmaurice GM, Ware JH. Applied Longitudinal Analysis. Hoboken:
John Wiley & Sons; 2004.
25. Barroso C, Correia-Pinto J. Thoracoscopic repair of congenital
diaphragmatic hernia, review of the results. Minerva Pediatr.
2017;70:281–288.
26. Wung JT, Sahni R,Moffitt ST, Lipsitz E, Stolar CJ. Congenital diaphragmatic
hernia: survival treatedwith very delayed surgery, spontaneous respiration,
and no chest tube. J Pediatr Surg. 1995;30:406–409.
27. IJsselstijn H, Tibboel D, Hop WJ, Molenaar JC, de Jongste JC. Long-
term pulmonary sequelae in children with congenital diaphragmatic
hernia. Am J Respir Crit Care Med. 1997;155:174–180.
28. Montgomery MFB, Freyschuss U, Mortensson W. Long-term-follow-
up of respiratory function, maximal working capacity, and esophageal
function. Pediatr Surg Int. 1995;10:519–522.
29. van der Cammen-van Zijp MHM, Janssen AJ, Raets MM, et al.
Motor performance after neonatal extracorporeal membrane
2 | TOUSSAINT-DUYSTER ET AL.636
oxygenation: a longitudinal evaluation. Pediatrics. 2014;134:
427–435.
30. MadderomMJ, Toussaint LCC, van der Cammen-van Zijp MHM, et al.
Congenital diaphragmatic hernia with(out) ECMO: impaired develop-
ment at 8 years. Arch Dis Child Fetal Neonatal Ed. 2013;98:316–322.
31. Smith LJ, van Asperen PP, McKay KO, Selvadurai H, Fitzgerald DA.
Reduced exercise capacity in children born very preterm. Pediatrics.
2008;122:287–293.
32. Cumming GR, Everatt D, Hastman L. Bruce treadmill test in children:
normal values in a clinic population. Am J Cardiol. 1978;41:69–75.
33. DahhanN,MeijssenD, ChegaryM, BosmanD,Wolf B. Ethnic diversity
outpatient clinic in paediatrics. BMC Health Serv Res. 2012;12:12.
34. Troe EJ, Raat H, Jaddoe VW, et al. Explaining differences in
birthweight between ethnic populations. The Generation R Study.
BJOG. 2007;114:1557–1565.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
How to cite this article: Toussaint-Duyster LCC, van der
Cammen-van Zijp MHM, de Jongste JC, et al. Congenital
diaphragmatic hernia and exercise capacity, a longitudinal
evaluation. Pediatric Pulmonology. 2019;1–9.
https://doi.org/10.1002/ppul.24264
54:628–636. 
